Non-hematologic ARs

The Side Effect Profile of ZEJULA Is Well-Characterized1

Side effects were manageable with dose interruption and modification.

  • ARs led to dose reduction or interruption in 69% of patients, most frequently from thrombocytopenia (41%) and anemia (20%)1,2
  • No increase in all-grade diarrhea was observed with ZEJULA vs placebo1
  • No on-treatment deaths were reported during the study2

References: 1. ZEJULA (niraparib) [package insert]. Waltham, MA: TESARO, Inc.; February 2019. 2. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164, and Supplementary Appendix.
 

Information on hematologic adverse reactions

HEMATOLOGIC ARs

See hematologic ARs

See Incidence Rates
Dosing information

DOSE MODIFICATIONS

See recommendations for dose adjustments

Review Dosing
Back to Top